Supernatant Synbiotic Formula

SUPERNATANT— The supernatant is designed to address hospital generated infections.*

Hospital generated infections: Take 2-4 during a hospital stay, or if infected with organisms such as C. difficile (causing diarrhea). It is used to address salmonella, food poisoning, yeast overgrowth, etc. It is also supportive with colitis, diverticulitis, and Crohn’s disease.*

Colds and flu: Take 1-2 capsules a day. Add 1 teaspoon of Lact ORNs and dissolve in mouth. Add 1-2 capsules of Garlic.*

ASD (autistic spectrum disorder): many health care providers find the Supernatant is well tolerated by children with ASD. If 1 capsule is too much, open up the capsule and mix half the amount of the powder with water.*

An everyday probiotic: Due to its strong protection and ability colonize and compete against pathogens, the Supernatant is an excellent choice for everyday probiotic. Take 1-2 daily as maintenance.*

Our Favorite: The Supernatant is such an advanced probiotic product. Our CEO, Seann Bardell, considers it his most favorite product, alongside the Garlic, Phyto Power,and Fructo Borate.

As a probiotic mix it helps even the most sensitive people!*

More Info:

Supernatant is the fermented medium created during the culturing process of probiotics. Supernatant is the fermented “soup” that contains important probiotic metabolites, such as enzymes, peptides, proteins, vitamins, short chain fatty acids, and other nutrients and factors, including antimicrobials such as Bacteriocins that may be used as a possible alternative to antibiotics (Cotter, Ross, & Hill, 2013; Yang et al., 2014). Supernatant, or as some call it, “postbiotic” (Auilar-Toalá et al., 2018), or “parabiotic” (Choudhury & Kamilya, 2018), is shown in research to have powerful antimicrobial properties with the potential to block adhesion, invasion and translocation of E. coli, yet it is gentle enough to be used to ‘enhance neonatal resistance to systemic Escherichia coli K1 infection by accelerating development of intestinal defense’ (He et al., 2017). In fact, Lazar et al.’s (2009) in vitro study concluded that the soluble probiotic metabolites, or supernatant, might actually interfere with the beginning stages of adherence and colonization of selected E. coli. This means that the supernatant itself exudes protective effects (Lazar et al., 2009), as well as work synergistically with probiotic organisms to stimulate the immune system against pathogenic invasion (Ditu et al., 2014).

Immunobiotics:  The combination of lactic acid bacteria (LAB) and their metabolites is given much consideration as a method to improve human immune response against viral and fungal overgrowth. The term “immunobiotic” is a relatively new way to describe the antimicrobial qualities exerted by probiotics and their metabolites (Arena et al., 2018). The term ‘immunobiotic’ has been proposed to define beneficial microbes with the ability to regulate the immune system and lower inflammation of the gut tissue (Villena & Kitazawa, 2017; Villena et al., 2016). For example, the probiotics L. rhamnosus and L. plantarum carry immunobiotic properties and are shown to increase protection against viral intestinal infections (Albarracin et al., 2017). In a different study on mice, Kikuchi et al. (2014) discovered that oral administration of L. plantarum enhanced IgA secretion in both intestine and lung tissues, supporting against influenza virus infection. Immunobiotics, the combination of probiotics and their supernatant metabolites, have been found to support and benefit respiratory immunity (Zelaya et al., 2016), modulate mucosal cytokine profiles, IgA levels, and more, in various conditions of gastrointestinal inflammation (Carvalho et al., 2017).

Bacteriocins and Antimicrobial Properties:  One of the properties that is given much attention is the bacterially produced antimicrobial peptides of bacteriocins (e.g., Cotter & Hill, 2013; Yang et al., 2014; Cotter et al., 2005). Already in 2005, Cotter & Hill observed that bacteriocin nisin functions by binding to lipid II, which is also the target of vancomycin antibiotic. This led to the suggestion that ‘bacteriocin nisin’ could be used as a template to design novel drugs. In 2018, the research to discover the mechanism of bacteriocin against pathogenic activity, including Staphylococcus aureus, continued with the discovery of critical features in the structure of bacteriocins that gives it such a ‘potent activity against pathogenic staphylococci’ (O’Connor et al., 2018).

Metabolic Disorders:  Intestinal dysbiosis and endotoxemia have been linked to metabolic disorders: obesity, insulin resistance, and type 2 diabetes (Leite et al., 2017). Bacterial lipopolysaccharides (LPS) is a molecular element of the outer membrane of Gram-negative bacteria, and typically consist of lipid A (or endotoxin), a ‘core’ oligosaccharide, and a distal polysaccharide, (or O-antigen). LPS also are found in diverse Gram-negative bacteria, many of which are pathogenic to both humans and plants (Raetz & Whitfield, 2002). LPS (also termed endotoxin) serves as a shield from the environment and at the same time is recognized by the immune system as a marker for the entrance (or invasion) of pathogens, which in turn causes inflammatory response, and in an extreme response can bring about endotoxic shock (Rosenfeld & Shai, 2006).  LPS causes inflammatory immunogens that circulate at low grade levels in healthy individuals, while high continuous levels instigate pro-inflammatory markers in the blood, e.g., interleukin-6, interleukin-1-alpha, interferon-gamma, triglycerides and post-prandial insulin. Proinflammatory markers are correlated with the risk of developing a variety of chronic illness, including increase risk of atherosclerosis (Erridge et al., 2007; see Cani et al., 2007).

Since the body is a mechanism of many interactive systems and components, a reaction in one system can instigate a positive or a negative chain of events in another. For example, in a clinical study, Leite et al. (2017) demonstrated that Gram-negative species (e.g., Bacteroides vulgatus and rodentium) were found in stools of individuals with type 2 diabetes, as well as an increase of pro-inflammatory interleukin-6 (IL-6) in their plasma. In other words, gut dysbiosis and metabolic endotoxemia have been linked to metabolic disorders, such as obesity, diabetes, and insulin resistance (van Olden et al., 2015). The gut microbiota contributes to many processes in the human host’s body, and the host provides a place of residence for the survival of the microorganisms (Leite et al., 2017). This give and take relationship has to be delicately balanced.

Epigenetic Changes: Bhat et al. (2017) considers dietary metabolites that are derived from the gut microbiotic population as critical modulators of epigenetic changes in both animals and humans.  Nutrients in the gut are produced by microbial metabolisms of fiber, which means that short-chain fatty acids, polyamines, polyphenols, vitamins, and other metabolites, participate in “various epigenomic mechanisms that reprogram the genome by altering the transcriptional machinery of a cell in response to environmental stimuli” (Bhat et al., 2017). In other words, what we eat does modulate our gut which in turn can influence our health through modulations of genes.

Potent Immune Boosting Nutrients: Adding the natural supernatant metabolic ‘soup’ of potent nutrients that probiotic organisms create while they grow and multiply is showing great potential for human health. Immunobiotics is a study field that endeavors to understand how microorganisms and their supernatant interact with the immune system to support a healthy functioning body (e.g., Górska et al., 2016). Studies on probiotics and their supernatant metabolites are ongoing and add much to our understanding of Turnbaugh et al. (2012) “supra-organism” description of our bodies as an amazing genome collective of human cells and ‘other’ cells.